Skip to content

Manupat Lohitnavy

4 papers in the library · 21 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans.

Toxicological sciences : an official journal of the Society of Toxicology November 1, 2025 Naphat Wittayakarn, Yu-Mei Tan, Pattanachai Choomalaiwong et al.

Ayahuasca is a traditional Amazonian brew composed of Psychotria viridis, containing N,N-dimethyltryptamine (DMT), and Banisteriopsis caapi, which includes harmala alkaloids such as harmine. Ayahuasca can produce potent psychoactive effects primarily due to DMT, whose metabolism is inhibited by harmine via monoamine oxidase-A enzymes. This inhibition increases DMT's systemic bioavailability,...

Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans.

Scientific Reports April 21, 2025 Nilubon Thaoboonruang, Ornrat Lohitnavy, Kimheang Ya et al. 4 citations

Psilocybin is an active alkaloid found in magic mushrooms (Psilocybe cubensis). It is classified as a Class I Psychoactive Substance due to its psychoactive properties. Recent research has suggested that psilocybin holds potential for treating major depressive disorder. The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for psilocybin and its active...

Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom ( Psilocybe cubensis ): A Systematic Review

Journal of Psychoactive Drugs September 10, 2024 Nilubon Thaoboonruang, Manupat Lohitnavy, Ornrat Lohitnavy 11 citations

Psilocybin, a major indole alkaloid found in magic mushrooms (Psilocybe cubensis), has recently drawn attention as a breakthrough therapy to treat major depressive disorder. This review aimed to summarize and identify knowledge gaps concerning their pharmacokinetic characteristics of psilocybin and its active metabolite, psilocin. Original studies related to pharmacokinetics of psilocybin...

Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans

F1000Research March 15, 2021 Prinya Musikaphongsakul, Kimheang Ya, Pakpoom Subsoontorn et al. 6 citations

Background: Psilocybin (PB) is a psychoactive compound commonly found in magic mushroom (Psilocybe cubensis). PB is quickly converted by the body to psilocin (PI), which has a psychedelic effect through the activation of the 5-HT2A receptor in the brain. The objective of this study is to develop a physiologically based pharmacokinetic (PBPK) model of PB and PI in rats and humans for predicting...